CompanyGraph
What stands out
- Most companies in its industry are risk businesses; this one is a production business
At a glance
- Depends onUpstream position: supplies 3 industries, depends on 0
- ScaleRevenue is $701,967, lower than 95% of all stocks globally
- PositionReturn on assets is -35290.6%, lower than 95% of its Shell Companies peers (median 2.1%)
What this company is and how it runs — written from structure, not news.
What stands out
- Most companies in its industry are risk businesses; this one is a production business
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
The statements on file don't all cover the same year: income statement FY2024, balance sheet FY2025, cash-flow statement FY2024. Each figure below is labelled with the year it comes from.
Financials view
Market Capitalization
286.70MUSDvs all stocks (USD)
Revenue (TTM)
701.97KUSDvs all stocks (USD)
52-Week Change
10.82%vs all stocks
Market Capitalization
286.70MUSDvs all stocks (USD)
Enterprise Value
285.41MUSDvs all stocks (USD)
Enterprise to Revenue
406.59xEnterprise to EBITDA
-5.97xvs Shell Companies peers
Revenue (TTM)
701.97KUSDvs all stocks (USD)
Revenue per Share (TTM)
0.4513USDUpdated Sep 28, 2026Gross Profit (TTM)
-2.45MUSDvs all stocks (USD)
EBITDA (TTM)
0.00USDvs all stocks (USD)
Net Income (TTM)
-187.58KUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
-100.00%vs Shell Companies peers
Operating Cash Flow (TTM)
-34.57MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-49.41MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 28, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Revenue
701.97KUSDFY2024 · Dec 31, 2024Cost of Goods Sold
3.15MUSDFY2024 · Dec 31, 2024Gross Profit
-2.45MUSDFY2024 · Dec 31, 2024Operating Income
-42.06MUSDvs all stocks (USD)
Pre-tax Income
-48.41MUSDFY2024 · Dec 31, 2024Net Income
-49.41MUSDFY2024 · Dec 31, 2024EBIT
-48.24MUSDFY2024 · Dec 31, 2024EBITDA (Income Statement)
-47.81MUSDFY2024 · Dec 31, 2024Selling, General & Administrative
39.61MUSDFY2024 · Dec 31, 2024Non-operating Interest Income
57.60KUSDFY2024 · Dec 31, 2024Non-operating Interest Expense
175.93KUSDFY2024 · Dec 31, 2024EPS (Basic)
-31.85USDFY2024 · Dec 31, 2024EPS (Diluted)
-31.85USDFY2024 · Dec 31, 2024Basic Shares Outstanding
1.56MSharesFY2024 · Dec 31, 2024Diluted Shares Outstanding
1.56MSharesFY2024 · Dec 31, 2024Operating Cash Flow
-34.57MUSDFY2024 · Dec 31, 2024Free Cash Flow
-34.65MUSDFY2024 · Dec 31, 2024Cash & Cash Equivalents (End of Period)
348.82KUSDFY2024 · Dec 31, 2024Starting Profit (CF Statement)
-48.41MUSDFY2024 · Dec 31, 2024Depreciation & Amortization
428.83KUSDFY2024 · Dec 31, 2024Stock-based Compensation
5.12MUSDFY2024 · Dec 31, 2024Other Non-cash Items
7.39MUSDFY2024 · Dec 31, 2024Change in Accounts Receivable (CF)
-367.30KUSDFY2024 · Dec 31, 2024Change in Accounts Payable (CF)
725.00KUSDFY2024 · Dec 31, 2024Change in Other Assets/Liabilities
549.07KUSDFY2024 · Dec 31, 2024Capital Expenditures
-85.67KUSDFY2024 · Dec 31, 2024Net Intangibles (CF)
417.44KUSDFY2024 · Dec 31, 2024Net Acquisitions
0.00USDFY2024 · Dec 31, 2024Purchase of Investments
-739.56KUSDFY2024 · Dec 31, 2024Sale of Investments
490.00KUSDFY2024 · Dec 31, 2024Other Investing Activity
-87.16KUSDFY2024 · Dec 31, 2024Net Investing Cash Flow
-422.38KUSDFY2024 · Dec 31, 2024Long-term Debt Issuance
0.00USDFY2024 · Dec 31, 2024Long-term Debt Payments
0.00USDFY2024 · Dec 31, 2024Other Financing Charges
943.72KUSDFY2024 · Dec 31, 2024Net Financing Cash Flow
15.53MUSDFY2024 · Dec 31, 2024Shares Outstanding
29.08MSharesUpdated Sep 28, 2026Float Shares
18.18MSharesUpdated Sep 28, 2026Shares Short
2.67KSharesUpdated Sep 28, 2026Short Ratio
0.0600daysvs all stocks
Short % of Shares Outstanding
0.01%vs all stocks
% Held by Insiders
0.96%vs all stocks
% Held by Institutions
0.06%vs all stocks
Total Cash (MRQ)
1.14MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
0.0390USDUpdated Sep 28, 2026Total Debt (MRQ)
0.00USDvs all stocks (USD)
Current Ratio (MRQ)
0.2300xvs Shell Companies peers
Book Value per Share (MRQ)
-0.4060USDUpdated Sep 28, 2026Total Assets
140.01KUSDvs all stocks (USD)
Total Current Assets
30.00KUSDFY2025 · Dec 31, 2025Total Liabilities
130.44KUSDFY2025 · Dec 31, 2025Total Non-current Assets
110.01KUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
-200.00USDFY2025 · Dec 31, 2025Total Current Liabilities
130.64KUSDFY2025 · Dec 31, 2025Short-term Debt
40.42KUSDFY2025 · Dec 31, 2025Common Stock (Book)
767.00USDFY2025 · Dec 31, 2025Retained Earnings
-15.63KUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
9.57KUSDvs all stocks (USD)
52-Week Low
1.14USDUpdated Sep 28, 202652-Week High
16.87USDUpdated Sep 28, 202652-Week Change
10.82%vs all stocks
50-Day MA
9.83USDUpdated Sep 28, 2026200-Day MA
9.83USDUpdated Sep 28, 2026Avg 10-Day Volume
6.31KSharesUpdated Sep 28, 2026Avg 30-Day Volume
35.20KSharesUpdated Sep 28, 2026Diluted EPS (TTM)
-31.85USDUpdated Sep 28, 2026Other Income / Expense
-6.24MUSDFY2024 · Dec 31, 2024Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Return on assets is -35290.6%, lower than 95% of its Shell Companies peers (median 2.1%)Significant
Return on assets: -352.906Industry median: 0.02Industry P5: -0.06Peers compared: 55.00
Structural Tensions
Most companies in its industry are risk businesses; this one is a production businessSignificant
Industry peers: 62.00Share on the common pattern %: 76.00
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -0.50
Supply Chain
Upstream position: supplies 3 industries, depends on 0Notable
Outgoing: 3.00Incoming: 0.00
Scale
Revenue is $701,967, lower than 95% of all stocks globallySignificant
Revenue (USD): 701,967Global P5: 33,357,653.812
Companies that share the same coordination system — how they create, deliver, or capture value.
Sichuan Gangtong Medical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Tiansheng Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Guangdong Jiaying Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Cresco Labs Inc.
Tier 1ProductionApproval-Gated PipelineFlowRule
Shanghai Hile Bio-Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
JBM
Tier 1ProductionApproval-Gated PipelineRuleFlow
Lavipharm S.A.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Animalcare Group Plc
Tier 1ProductionApproval-Gated PipelineRuleFlow
Guiyang Xintian Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Green Cross Holdings Corp.
Tier 1ProductionApproval-Gated PipelineRuleFlow